Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 1.00 |
| ▸ | PPARG | P37231 | 9/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29547028 | 1.00 | FFAR1 (1.00) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL7835250 | 0.85 | PPARG (0.73) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL23465376 | 0.81 | FFAR1 (0.69) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL6508034 | 0.81 | FFAR1 (0.68) | FFAR1PPARGPPARA | |
| SCHEMBL1072226 | 0.79 | FFAR1 (0.77) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL9143087 | 0.78 | FFAR1 (0.64) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL8128813 | 0.77 | PPARG (0.63) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL7512050 | 0.77 | FFAR1 (0.63) | FFAR1PPARGPPARA | |
| SCHEMBL9570670 | 0.77 | FFAR1 (0.71) | FFAR1PPARGHRH3PPARA | |
| SCHEMBL7837259 | 0.77 | FFAR1 (0.63) | FFAR1PPARGHRH3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931350-B2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-08-04 | — | — | EP | claimed |
| EP-1942898-B2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2014-05-14 | — | — | EP | claimed |
| EP-1931350-B1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2013-11-20 | — | — | EP | claimed |
| US-8338480-B2 | Combination treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| EP-1942898-B1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | claimed |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-09-01 | — | — | US | claimed |
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-08-11 | — | — | US | claimed |
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-11-18 | — | — | US | claimed |
| EP-1942898-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | Takeda Pharmaceutical Company Limited (JP) | 2008-07-16 | — | — | EP | claimed |
| EP-1931350-A2 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2008-06-18 | — | — | EP | claimed |
| WO-2007033266-A2 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETIS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| WO-2007033350-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS FOR TREATING DIABETES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-22 | — | — | WO | claimed |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DEVELOPMENT PARTNERS, LLC | 2007-03-15 | — | — | US | claimed |
| US-20070060530-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | TAKEDA SAN DIEGO, INC. | 2007-03-15 | — | — | US | claimed |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2025-01-28 | — | — | US | disclosed |
| US-20240036046-A1 | CANCER EXAMINATION METHOD AND CANCER TREATMENT AGENT | IMAMITSUKAI MEDICAL CORPORATION (JP) | 2024-02-01 | — | — | US | disclosed |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-5977365-A | HYPOGLYCEMIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1999-11-02 | — | — | US | disclosed |
| US-5624935-A | ANTIDIABETIC AGENTS, HYPOGLYCEMIC AGENTS OR ANTILIPEMIC AGENTS | SANKYO COMPANY, LIMITED | 1997-04-29 | — | — | US | disclosed |
| EP-0676398-A2 | Heterocyclic compounds having anti-diabetic activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1995-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110192748-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | FFAR1 1719/4885PPARG 2134/4885HRH3 3067/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FFAR1 256/4885PPARG 3245/4885HRH3 2147/4885 |
| US-20100292277-A1 | COMBINATION TREATMENT OF METABOLIC DISORDERS | NR1H3, GPR119, NR1H2 | FFAR1 6/4885PPARG 12/4885HRH3 293/4885 |
| US-20070060530-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP4, DPP7, DPP3 | FFAR1 1719/4885PPARG 2134/4885HRH3 3067/4885 |
| US-20110212982-A1 | Administration of Dipeptidyl Peptidase Inhibitors | DPP4, DPP7, DPP3 | FFAR1 2426/4885PPARG 2282/4885HRH3 2934/4885 |
| US-12209144-B2 | Cyclic peptides as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FFAR1 1045/4885PPARG 3421/4885HRH3 1895/4885 |
| US-20070060529-A1 | ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS | DPP7, DPP4, DPP3 | FFAR1 1866/4885PPARG 1967/4885HRH3 3326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.